0.6815
Precedente Chiudi:
$0.751
Aprire:
$0.7285
Volume 24 ore:
154.68K
Relative Volume:
1.20
Capitalizzazione di mercato:
$86.53M
Reddito:
-
Utile/perdita netta:
$-70.78M
Rapporto P/E:
-1.2169
EPS:
-0.56
Flusso di cassa netto:
$-61.27M
1 W Prestazione:
-23.06%
1M Prestazione:
-43.57%
6M Prestazione:
-74.80%
1 anno Prestazione:
-74.13%
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Nome
Nautilus Biotechnology Inc
Settore
Industria
Telefono
206-333-2001
Indirizzo
2701 EASTLAKE AVE EAST, SEATTLE
Confronta NAUT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NAUT
Nautilus Biotechnology Inc
|
0.6816 | 86.53M | 0 | -70.78M | -61.27M | -0.56 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
481.68 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
587.39 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
559.38 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
244.97 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
240.59 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-05 | Downgrade | Goldman | Neutral → Sell |
2024-06-27 | Iniziato | Guggenheim | Buy |
2024-06-03 | Ripresa | Jefferies | Hold |
2022-01-06 | Iniziato | Morgan Stanley | Equal-Weight |
2021-11-02 | Iniziato | Cowen | Outperform |
2021-08-04 | Iniziato | Goldman | Neutral |
2021-07-13 | Iniziato | Jefferies | Buy |
Mostra tutto
Nautilus Biotechnology Inc Borsa (NAUT) Ultime notizie
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Position Decreased by Charles Schwab Investment Management Inc. - Defense World
Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
We're Keeping An Eye On Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate - Yahoo Finance
Nautilus Biotechnology: Hold Rating Amid Delayed Launch and Strategic Adjustments - TipRanks
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript - Insider Monkey
Nautilus Biotechnology lays off 16% of workforce, plans release of commercial platform in 2026 - MSN
Nautilus: Trading Below An Albeit Lower Net Cash Figure (NASDAQ:NAUT) - Seeking Alpha
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating - Investing.com
Guggenheim cuts Nautilus Biotech target to $2.50, keeps buy rating By Investing.com - Investing.com South Africa
Nautilus Biotechnology Reports 2024 Financial Results - TipRanks
Seattle's Nautilus Biotechnology lays off 16% of its staff - The Business Journals
Nautilus Biotechnology Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Nautilus Q4 2024 highlights platform delay - Investing.com
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024 - Marketscreener.com
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Manila Times
Nautilus Cuts 16% of Workforce as Biotech Platform Launch Slips to 2026What's Next? - StockTitan
Nautilus Biotechnology Announces Board Changes for 2025 - TipRanks
Nautilus Biotechnology (NAUT) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Blade Air Mobility Leads The Charge Among 3 US Penny Stocks - Simply Wall St
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference - The Manila Times
Exclusive: Nautilus Biotech Unveils Next-Gen Protein Analysis Breakthrough at Major Healthcare Summit - StockTitan
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 68.8% in January - MarketBeat
Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Down 5.9%Time to Sell? - MarketBeat
SG Americas Securities LLC Buys 9,904 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
NAUTNautilus Biotechnology Inc Latest Stock News & Market Updates - StockTitan
Nautilus Bio Q4 Earnings Alert: Protein Analysis Pioneer Reports Feb 27 - StockTitan
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - GlobeNewswire
One Nautilus Biotechnology Insider Raised Their Stake In The Previous Year - Yahoo Canada Finance
Nautilus Biotech announces board member changes By Investing.com - Investing.com Australia
Nautilus Biotech announces board member changes - MSN
Nautilus Biotechnology Announces Board Member Departures - MSN
NAUTILUS BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Barclays PLC Buys 47,059 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
Jeff Bezos Stock Portfolio: Top Investment Picks - CoinCodex
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Short Interest Down 14.2% in December - MarketBeat
Barclays PLC Has $1.04 Million Holdings in Northfield Bancorp, Inc. (Staten Island, NY) (NASDAQ:NFBK) - Defense World
Jane Street Group LLC Sells 25,020 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
EZCORP, Inc. (NASDAQ:EZPW) Shares Acquired by Barclays PLC - Defense World
US Penny Stocks To Watch In January 2025 - simplywall.st
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Barclays PLC Has $303,000 Stock Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
State Street Corp Lowers Holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
The Manufacturers Life Insurance Company Invests $67,000 in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) - Defense World
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks - Simply Wall St
Nautilus Biotechnology Inc Azioni (NAUT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nautilus Biotechnology Inc Azioni (NAUT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):